1. Home
  2. ANGI vs URGN Comparison

ANGI vs URGN Comparison

Compare ANGI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANGI
  • URGN
  • Stock Information
  • Founded
  • ANGI 1995
  • URGN 2004
  • Country
  • ANGI United States
  • URGN United States
  • Employees
  • ANGI N/A
  • URGN N/A
  • Industry
  • ANGI Advertising
  • URGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANGI Consumer Discretionary
  • URGN Health Care
  • Exchange
  • ANGI Nasdaq
  • URGN Nasdaq
  • Market Cap
  • ANGI 809.7M
  • URGN 896.3M
  • IPO Year
  • ANGI 2017
  • URGN 2017
  • Fundamental
  • Price
  • ANGI $18.30
  • URGN $19.71
  • Analyst Decision
  • ANGI Hold
  • URGN Strong Buy
  • Analyst Count
  • ANGI 8
  • URGN 8
  • Target Price
  • ANGI $21.17
  • URGN $27.75
  • AVG Volume (30 Days)
  • ANGI 792.9K
  • URGN 1.3M
  • Earning Date
  • ANGI 08-05-2025
  • URGN 08-07-2025
  • Dividend Yield
  • ANGI N/A
  • URGN N/A
  • EPS Growth
  • ANGI N/A
  • URGN N/A
  • EPS
  • ANGI 1.20
  • URGN N/A
  • Revenue
  • ANGI $1,088,722,000.00
  • URGN $94,238,000.00
  • Revenue This Year
  • ANGI N/A
  • URGN $39.80
  • Revenue Next Year
  • ANGI $3.67
  • URGN $108.94
  • P/E Ratio
  • ANGI $15.24
  • URGN N/A
  • Revenue Growth
  • ANGI N/A
  • URGN 10.85
  • 52 Week Low
  • ANGI $10.88
  • URGN $3.42
  • 52 Week High
  • ANGI $29.15
  • URGN $21.02
  • Technical
  • Relative Strength Index (RSI)
  • ANGI 59.94
  • URGN 62.57
  • Support Level
  • ANGI $17.41
  • URGN $17.21
  • Resistance Level
  • ANGI $18.58
  • URGN $20.55
  • Average True Range (ATR)
  • ANGI 0.74
  • URGN 1.21
  • MACD
  • ANGI 0.13
  • URGN -0.18
  • Stochastic Oscillator
  • ANGI 72.48
  • URGN 66.92

About ANGI Angi Inc.

Angi Inc connects quality home service professionals with consumers across different categories, from repairing and remodeling to cleaning and landscaping. It operates through brands like Angi, HomeAdvisor, and Handy. The company has three operating segments, namely, Ads and Leads, Services, and International (Europe and Canada). A majority of its revenue is generated from the Ads and Leads segment, which provides professionals the capability to engage with potential customers, including quoting and invoicing services, and provides consumers with tools and resources to help them find professionals nationwide for home repair, maintenance, and improvement projects. Geographically, the company derives its key revenue from the United States and also has a presence in other countries.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: